Baird Rates Abbott Laboratories (ABT) buy, $121 Price Target
Analyst David Rescott keeps a buy rating and a $121 price target on Abbott Laboratories in an update published on July 1, 2026, a 33.11% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Baird rated Abbott Laboratories ($ABT) "buy" with a $121 price target on July 1, 2026.
Since the rating, $ABT is up 3.2% after 1 week, up 15.5% after 1 month and up 15.3% to date (from the $90.97 close on Jul 1, 2026).
ABT
Abbott Laboratories
Key Points
- Baird analyst David Rescott kept a buy rating on Abbott Laboratories NYSE ABT with a $121 price target on July 1, 2026.
- Baird's $121 price target implies 33.11% upside from Abbott Laboratories's ($ABT) current $90.90 share price.
- Abbott Laboratories trades near $90.90, positioned below its 52-week high of $132.03 and above its low of $81.97.
- Wall Street maintains a strong consensus opinion on the healthcare giant backed by 26 analyst reviews and a mean price target of $120.72.
Get $ABT trade alerts by text
We text you when insiders, Congress or big funds trade $ABT. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Abbott Laboratories alert may contain errors. Disclosures
Baird Keeps Buy Rating on Abbott Laboratories
Baird reaffirmed its positive view on Abbott Laboratories NYSE ABT on July 1, 2026, keeping a buy rating and a $121 price target on the healthcare equipment maker. Analyst David Rescott kept the firm's prior target in place, joining a busy stretch of updates from major Wall Street research desks regarding the medical device provider.
Baird vs. the S&P 500
Hypothetical returns from Baird's disclosed trades, not real profit or advice. How we model this.
Analysts Set New Price Targets
Other research firms have kept close tabs on the stock through late summer and autumn. On October 16, 2026, TD Cowen reiterated its buy rating with a $135 price target. Earlier in October, Barclays started coverage with an overweight rating and a $120 price target, while Rothschild and Company bumped its rating to a buy with a $127 target on October 2, 2026. Citigroup also checked in on August 14, 2026, maintaining a buy rating and setting a $125 price target, and Wolfe Research upgraded the shares to an outperform with a $130 target on August 13, 2026.
Taking all recent views together, the wider market maintains a strong buy recommendation key across 26 tracked analyst opinions. The mean price target sits at $120.72, with individual estimates ranging from a low of $103 up to a high of $135.
Stock Performance and Valuation
Shares recently changed hands at $90.90 on Wednesday. That puts the equity well below its 52-week high of $132.03 and somewhat above its 52-week low of $81.97. The company sports a market capitalization near $181.14 billion and a forward P-E ratio of 17.26, based on upcoming earnings estimates.
$ABT price target
Abbott Laboratories daily closes and this analyst's $121 target. Not advice.
Abbott Laboratories Financial Foundation
Abbott Laboratories operates four core segments spanning medical devices, diagnostic systems, nutritional products, and established pharmaceuticals. The company generates steady revenue through a broad mix of global health solutions, backed by a net margin of 11.6% and a return on equity of 10.6% over trailing periods. Investors looking ahead to the next financial checkpoint should note that the company is scheduled to report its next quarterly earnings on October 21, 2026.
What to Watch Next for Abbott Laboratories
With the upcoming earnings release set for late October, market watchers will track whether quarterly revenue growth matches recent trends. Baird's reaffirmed target keeps the spotlight on how execution in medical devices and diagnostics drives share movement heading toward the end of the year.
Related Filing Alerts
Source: Baird's rating change on $ABT (Jul 1, 2026). Written by software, not financial advice. How we make alerts